VEEV › analyze
VEEV · Analyze
Date: 2026-04-28 Price at Analysis: ~$158.49 | 52-wk Range: $148.05 – $310.50 Market Cap: ~$26.1B | Sector: Healthcare (Life Sciences SaaS) Fiscal Year: Ends January 31
Company Overview
Veeva Systems is the dominant cloud software platform for the global life sciences industry — biopharma, biotech, clinical research, and medical device companies. Its two primary cloud suites are:
- Commercial Cloud — CRM, marketing, medical affairs (Vault CRM replacing legacy Veeva CRM on Salesforce)
- Development Cloud — Clinical, regulatory, quality management (Vault platform; 21 CFR Part 11 validated)
Veeva also operates OpenData (HCP/HCO reference data), Crossix (patient-level data), and an expanding Data Cloud across the life sciences value chain.
FUNDAMENTALS ANALYST
Income Statement Summary (FY ends Jan 31)
| Metric | FY2023 | FY2024 | FY2025 | FY2026 | 3yr CAGR |
|---|---|---|---|---|---|
| Revenue | $2,155M | $2,364M | $2,747M | $3,195M | +14.0% |
| Gross Profit | $1,546M | $1,686M | $2,047M | $2,413M | +16.0% |
| Operating Income | $459M | $429M | $691M | $916M | +25.9% |
| Net Income | $488M | $526M | $714M | $909M | +23.1% |
| Diluted EPS | $3.00 | $3.22 | $4.32 | $5.44 | +22.0% |
Margin Trend
| Margin | FY2023 | FY2024 | FY2025 | FY2026 | Trend |
|---|---|---|---|---|---|
| Gross Margin | 71.7% | 71.3% | 74.5% | 75.5% | ↑ Expanding |
| Operating Margin | 21.3% | 18.2% | 25.2% | 28.7% | ↑ Strong leverage |
| Net Margin | 22.6% | 22.2% | 26.0% | 28.4% | ↑ Expanding |
FY2024 operating margin dip reflects deliberate R&D investment cycle (Vault CRM build). The recovery to 28.7% in FY2026 is a resolution of that investment.
Free Cash Flow
| FY2023 | FY2024 | FY2025 | FY2026 | 3yr CAGR | |
|---|---|---|---|---|---|
| Operating CF | $780M | $911M | $1,090M | $1,415M | +22.1% |
| FCF (reported) | $780M | $911M | $1,090M | $1,415M | +22.1% |
| SBC (add-back) | $352M | $394M | $437M | $473M | |
| SBC-adj FCF | $428M | $517M | $653M | $942M | +30.2% |
| SBC as % FCF | 45% | 43% | 40% | 33% | ↓ Improving |
SBC flag: SBC remains significant ($473M vs $909M net income = 52%), but as a percentage of FCF it is declining year over year. The real cash earnings power is growing. SBC-adjusted FCF of $942M is the conservative metric to use.
Per-Share Metrics
| FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|
| Revenue/share (basic) | $13.86 | $14.73 | $16.97 | $19.51 |
| FCF/share (diluted) | $4.80 | $5.57 | $6.60 | $8.47 |
| EPS (diluted, GAAP) | $3.00 | $3.22 | $4.32 | $5.44 |
Revenue/share CAGR (3yr): +12.1% | FCF/share CAGR (3yr): +20.8%
Shares Outstanding
| FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|
| Basic shares | 155.4M | 160.5M | 161.9M | 163.7M |
| Diluted shares | 162.4M | 163.5M | 165.2M | 167.0M |
| Change | — | +1.7M | +1.7M | +1.8M |
Modest dilution of ~1.1%/yr from SBC. In FY2026, Veeva initiated its first-ever buyback ($170M executed), and announced a $1B buyback authorization alongside Q4 FY2026 earnings (March 2026). This is a meaningful capital return signal and partially offsets SBC dilution going forward.
Balance Sheet (FY2026)
| Item | Value | Assessment |
|---|---|---|
| Cash + Short-term investments | $6,561M | 73% of total assets |
| Accounts Receivable | $1,260M | Healthy, growing with revenue |
| Total Assets | $8,979M | |
| Total Debt (leases only) | $96M | Essentially debt-free |
| Total Liabilities | $1,765M | 80% is deferred revenue — a liability that earns future income |
| Common Equity | $7,215M | |
| Tangible Book Value | $6,745M | Growing at +28%/yr: $3.2B→$6.7B over 3 years |
| Debt-to-Assets | 1.1% | Fortress balance sheet |
| Cash per diluted share | $39.28 | 25% of current stock price |
Capital Allocation Breakdown
| Use | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Acquisitions | $0 | $0 | $0 | $0 |
| Buybacks | $0 | $0 | $0 | $170M |
| Dividends | $0 | $0 | $0 | $0 |
| Balance sheet accumulation | ~$780M | ~$911M | ~$1,090M | ~$1,245M |
Veeva is unusual in retaining essentially all FCF on the balance sheet (now $6.56B in liquid assets). The $1B buyback authorization announced in March 2026 signals management believes the stock is undervalued and marks a strategic shift toward shareholder returns. No acquisitions in 3+ years — disciplined capital allocation.
ROIC Analysis
| FY2026 | |
|---|---|
| NOPAT = Operating Income × (1 – tax rate) | $916M × (1 – 0.239) = $697M |
| Invested Capital (net: excl. excess cash) | ~$420M |
| ROIC | ~166% |
ROIC is extraordinary, reflecting: (1) asset-light SaaS model, (2) negative working capital (customers prepay subscriptions), (3) minimal capex. Even using total equity as the denominator: $697M / $7,215M = 9.7% — still solid for a business holding $6.5B of cash that drags the return.
FY2027 Guidance (reported March 4, 2026)
- Revenue: $3,585–$3,600M (+12.3–12.5% growth)
- Non-GAAP Operating Income: ~$1,590M (44% of midpoint revenue)
- Non-GAAP EPS: ~$8.85
Fundamentals verdict: Exceptional across every dimension. FCF CAGR of 22%, expanding margins, fortress balance sheet, no debt, share count barely growing, first buyback program initiated. The only flag worth monitoring is SBC, which is declining as a percentage but still substantial in absolute terms.
MOAT ANALYST
ROIC + Gross Margin Trends
| FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|
| Gross Margin | 71.7% | 71.3% | 74.5% | 75.5% |
| Operating Margin | 21.3% | 18.2% | 25.2% | 28.7% |
| ROIC (adj.) | ~120% | ~130% | ~150% | ~166% |
Gross margin expansion and ROIC acceleration are both positive moat signals — the business is becoming more profitable per incremental dollar of revenue, which is what you want to see from a durable competitive advantage.
Moat Sources
1. Compliance-Validated Systems (Structural Barrier) Life sciences software must meet FDA's 21 CFR Part 11 (electronic records), ICH guidelines, and GxP validation requirements. Every Veeva application is pre-validated for these standards. This is not table-stakes — it takes years and significant regulatory expertise to build and maintain a validated software suite. A competitor entering this space must first invest years building the compliance infrastructure before selling a single module.
2. Switching Costs (Extreme) A pharma company running clinical trial data, regulatory submissions, medical affairs workflows, and HCP engagement on Vault cannot casually migrate. The cost and risk of switching is enormous: - Regulatory continuity requirements (historical data must be maintained in validated systems) - FDA inspection readiness (all system changes must be documented, validated, and auditable) - User retraining across thousands of field reps - Integration points with ERP, lab systems, and supply chain software
This creates near-permanent stickiness once embedded. Even if a competitor were cheaper, the operational risk of switching often exceeds the cost savings.
3. Proprietary Data Network Effects Veeva OpenData contains validated contact and affiliation data for millions of HCPs/HCOs globally. Crossix patient-level de-identified data is used for marketing analytics. Veeva Link aggregates clinical opinion leader intelligence. These datasets are built over years of industry-specific collection — a new entrant cannot replicate them quickly, and they become more valuable as more pharma companies contribute and rely on them.
4. Vault Platform Breadth → Expansion Revenue Veeva has expanded from CRM into Quality, Regulatory, Clinical, Safety, and Medical, all on the unified Vault platform. Each new module is a natural upsell into the existing customer base. This platform breadth creates a "land and expand" model that compounds revenue with minimal incremental customer acquisition cost.
Adversarial Stress Test — How Would a Rival Attack?
Attack vector 1: Salesforce Life Sciences Cloud + IQVIA The most credible threat. Salesforce launched its Life Sciences Cloud (GA September 2025) built on IQVIA's OCE platform with Agentforce AI and IQVIA's ADA analytics. AstraZeneca and Novartis have committed. Pfizer and Takeda are also named.
Moat defense: IQVIA's OCE is a legacy product that Salesforce has wrapped with cloud infrastructure — not a ground-up rebuild like Vault CRM. Salesforce brings AI and CRM expertise but lacks Veeva's deep regulatory compliance heritage, life-sciences data assets, and multi-product ecosystem. As of early 2026, Veeva has 10+ top-20 pharma committed vs Salesforce's 3-4. The 2026–2029 migration window is the decisive period. Veeva's position: favored but not guaranteed.
Attack vector 2: Vertical AI Agents (replacing SaaS workflows entirely) Could a pharma company deploy AI agents to replace commercial field rep software? Unlikely in regulated workflows. FDA requires auditable, validated systems with human-in-the-loop controls. AI agents operating outside a validated system create regulatory risk that pharma legal/compliance teams will not accept. AI will enhance Veeva's platform (Veeva AI Agents launched December 2025), not replace it.
Attack vector 3: Internal build by large pharma Theoretically possible for a J&J or Pfizer, but historically unsustainable. The operational burden of maintaining validated software in-house is enormous, and pharma companies' core competency is drug development, not software engineering. No large pharma has successfully internalized its CRM and content management at scale.
Disruption Forecast (5-year horizon)
- Salesforce: Wins market share at the margins, 15-25% of new enterprise wins. Co-existence is the most likely outcome — some functions stay on Veeva (Development Cloud, Quality), commercial HCP engagement splits.
- AI Agents: Enhance rather than disrupt. Veeva's AI Agent suite (December 2025) is an early mover. Veeva's unique data + validated-system requirement is a structural moat against pure AI replacement.
- New entrant: Very low probability. Compliance barriers plus 15-year head start make entry economics unattractive.
Evergreen Rating: HIGH
Life sciences R&D is not cyclical — drug development occurs regardless of economic conditions, and regulatory requirements for software are increasing, not decreasing. The FDA's push toward electronic submissions, real-world evidence, and digital health creates more demand for Veeva's infrastructure, not less.
Moat verdict: Wide moat. The combination of compliance barriers, switching costs, proprietary data, and platform breadth creates a durable competitive advantage. The Salesforce threat is the most credible risk but does not threaten the moat's core — it affects market share at the margins, not the underlying business model. The Vault CRM migration creates temporary uncertainty (2026–2029) but successful execution locks in another decade of dominance.
VALUATION ANALYST
Note: No dividend → DDM and DYT not applicable. Graham's formula applied with growth extension. Bogle model used. FCF-based intrinsic value as primary anchor.
Key Valuation Inputs
| Input | Value |
|---|---|
| Current price | ~$158.49 |
| Market cap | ~$26.1B |
| Net cash (cash – debt) | $6,561M – $96M = $6,465M |
| Enterprise Value | ~$19.6B |
| GAAP EPS (FY2026) | $5.44 |
| Non-GAAP EPS guidance (FY2027) | $8.85 |
| FCF (FY2026) | $1,415M |
| SBC-adjusted FCF | $942M |
| FCF/share (diluted) | $8.47 |
| Tangible BVPS | $41.18 |
Model 1: Graham Extended Intrinsic Value
Formula: IV = EPS × (8.5 + 2g) - Conservative (g = 12%): $5.44 × (8.5 + 24) = $5.44 × 32.5 = $176.80 - Base (g = 15%): $5.44 × (8.5 + 30) = $5.44 × 38.5 = $209.44 - Graham IV range: $177 – $209 - Current price ($158) is 11–24% below this range.
Graham's basic formula (√(22.5 × EPS × BVPS)): √(22.5 × $5.44 × $41.18) = √($5,044) = $71.03 — this is expected; Graham's formula assumes no growth and low P/E. Not relevant for a growth compounder. Extended formula is appropriate here.
Model 2: Bogle Expected Return
- Dividend yield: 0% (no dividend)
- Forward earnings growth: 15% (blend of 22% historical CAGR and 12% FY2027 guidance)
- P/E change: Trailing PE 29x → normalized 22x over 5 years = ~-5% headwind on P/E
- Bogle Expected Annual Return: 0% + 15% – 5% = ~10%/yr
At 10%/yr expected return, VEEV at $158 is an attractive entry for a long-horizon investor. If P/E holds at 29x (unlikely but possible in a market re-rating), the return rises toward 15%/yr.
Model 3: EV/FCF-Based Intrinsic Value
| Scenario | Assumption | Implied Fair Value |
|---|---|---|
| Bear (12% FCF CAGR, 18x terminal P/FCF) | Conservative growth, P/E compression | ~$145–$160 |
| Base (17% FCF CAGR, 22x terminal P/FCF) | Moderate growth, slight P/E re-rate | ~$185–$215 |
| Bull (22% FCF CAGR, 28x terminal P/FCF) | Continued compounding, multiple recovery | ~$280–$320 |
Base case fair value: $185–$215**
On an EV/SBC-adjusted FCF basis (most conservative): - EV: $19.6B / Adj FCF: $942M = 20.8x EV/adj FCF - For a business growing adj FCF at 30%+ CAGR: this is remarkably cheap - PEG on adj FCF: 20.8x / 30% = 0.69x — this is the most compelling valuation metric
Valuation Summary
| Metric | Current | Assessment |
|---|---|---|
| Trailing PE | 29.1x | Fair for quality |
| Forward PE (GAAP est.) | ~24x | Reasonable |
| Forward PE (non-GAAP) | ~18x | Attractive |
| EV/FCF (reported) | 13.9x | Cheap |
| EV/SBC-adj FCF | 20.8x | Attractive |
| Price/Graham Extended IV | 0.76x–0.90x | 10-24% discount |
| Price/DCF base case | 0.74x–0.86x | 14-26% discount |
| Cash as % of market cap | 24.7% | Substantial cushion |
Valuation verdict: VEEV is trading at a 10–26% discount to intrinsic value across models. The most compelling metric is EV/SBC-adj FCF of 20.8x against 30%+ adj FCF CAGR — a sub-1x PEG on the most conservative cash flow measure. The stock is not "dirt cheap" in an absolute sense, but relative to its quality and growth trajectory, it is meaningfully undervalued. The net cash position of $6.5B ($39/share) provides a substantial margin of safety.
SENTIMENT & INTELLIGENCE ANALYST
Q4 FY2026 Earnings (March 4, 2026)
- Q4 Revenue: $836M, +16% YoY — beat guidance
- Full-year FY2026 Revenue: $3,195M, +16% YoY
- Non-GAAP Q4 Operating Income: $366M (44% margin)
- Stock surged +11% on earnings day before broad SaaS selloff resumed
- FY2027 guidance: $3.585–3.600B revenue (+12.3%), non-GAAP EPS ~$8.85
CEO Peter Gassner (March 4 earnings call): "The agentic transformation underway represents a substantial opportunity for Veeva and life sciences. With our core systems of record spanning the industry's most critical functions and unique datasets, we can deliver industry-specific AI deeply integrated into our applications."
Analyst Consensus
| Period | Strong Buy | Buy | Hold | Sell |
|---|---|---|---|---|
| Current | 8 | 14 | 7 | 1 |
| -1 month | 9 | 14 | 8 | 1 |
| -2 months | 9 | 15 | 8 | 1 |
| -3 months | 9 | 14 | 8 | 2 |
73% Buy/Strong Buy, 23% Hold, 3% Sell. Analyst conviction has been remarkably stable even as the stock fell 50%+ from highs. GF Value estimates fair value at $277.16 vs current price $157 — a 76% gap. The consensus is strongly bullish; the selling is market-driven, not analyst-driven.
Institutional Ownership (Dec 31, 2025 snapshot)
| Holder | % Held | 1-Qtr Change |
|---|---|---|
| Vanguard Group | 9.41% | -0.39% (minimal) |
| BlackRock | 7.01% | +2.17% (adding) |
| AllianceBernstein | 3.58% | -1.63% (trimming) |
| Fidelity (FMR) | 3.37% | -16.45% (significant cut) |
| State Street | 2.20% | +2.45% (adding) |
| T. Rowe Price | 2.20% | -8.18% (trimming) |
| JPMorgan | 1.54% | -63.73% (major cut) |
Total institutional ownership: ~88%. Mixed signal — BlackRock and State Street are adding, while Fidelity and JPMorgan made significant reductions. Fidelity's 16% cut and JPMorgan's 63% reduction during Q4 2025 (before the big selloff) may reflect sector rotation or mandate-driven repositioning. Overall institutional base remains very strong.
Insider Activity
- Net insider activity (90 days): Net sellers, 24,665 shares, ~$7.44M
- Director Priscilla Hung sold 750 shares at $153.50 on April 10, 2026 (at 52-wk low)
- Insider Thomas Schwenger sold 1,000 shares at $231.43 in January 2026
- CEO Peter Gassner — founder and significant shareholder; no major insider selling flagged at large scale
Assessment: Small insider sales at depressed prices are routine (likely pre-planned 10b5-1 programs). The $7.44M in insider sales is trivial relative to a $26B market cap. Not alarming. No pattern of significant insider distribution.
Competitive News (Key Signal)
- AstraZeneca, Novartis, Pfizer, Takeda selected Salesforce Life Sciences Cloud/Agentforce for HCP engagement (2025–2026)
- Roche, GSK, Novo Nordisk International committed to Veeva Vault CRM — 10+ of top 20 pharma as of Q4 FY2026, expecting 14+ by FY2027 end
- Veeva AI Agents (Pre-call, Voice, Quick Check, Content Agent) launched December 2025 — multiple customers already live
- The migration window (2026–2029) is the decisive competitive period. The outcome of Vault CRM adoption among the remaining uncommitted top-20 pharma will determine the competitive equilibrium.
Sector Macro
The broader SaaS selloff (the "SaaS-pocalypse") is the primary driver of VEEV's stock decline, not company-specific deterioration. The stock surged 11% on earnings (March 5) confirming execution is strong, then fell back as sector selling resumed. This disconnect between business performance and stock price is the core opportunity.
Sentiment verdict: Business fundamentals are strong; sentiment is weak due to sector macro and Salesforce competitive concerns. The 73% analyst buy rate and 88% institutional ownership signal that informed capital has not abandoned the thesis. The Salesforce competitive threat is a genuine risk factor but not an existential one. The Fidelity and JPMorgan institutional cuts warrant monitoring.
PHASE 3 — TENSION: MOAT vs SENTIMENT
The dispute: Moat Analyst sees Salesforce's top-20 wins (AstraZeneca, Novartis) as manageable market-share friction at the margins. Sentiment Analyst notes that 4 named pharma giants (AstraZeneca, Novartis, Pfizer, Takeda) choosing Salesforce represents a more serious competitive signal than originally priced.
Rebuttal (Moat): "AstraZeneca's decision to select Salesforce Agentforce for HCP engagement is notable, but HCP engagement is only one module. Veeva's real stickiness is in Development Cloud (clinical, regulatory, quality) — the most compliance-sensitive, highest-switching-cost products. AstraZeneca may use Salesforce for commercial engagement while still running on Veeva Vault for regulatory and quality. The 'Salesforce vs Veeva' framing is too binary — co-existence is the realistic outcome."
Rebuttal (Sentiment): "The trend matters as much as the snapshot. If the top-20 pharma split is 14:6 in Veeva's favor by FY2027 (as guided), that's still dominant. But if it moves to 12:8 or 10:10, the narrative shifts. The migration window is live, and Veeva needs to execute."
Resolution: Weight toward Moat's position for the following reasons: (1) Veeva's non-CRM products (Vault, regulatory, clinical, quality) face essentially zero Salesforce competition — these are the highest-margin, highest-stickiness modules; (2) CEO guidance of 14+ top-20 commitments by FY2027 is a specific, trackable metric; (3) even a co-existence outcome (7 Salesforce, 13 Veeva) is consistent with ~15% revenue growth. The tension is named as Risk Factor #1 and warrants a quarterly monitoring cadence.
FINAL SYNTHESIS — MANAGER'S VERDICT
Score Card
| Dimension | Rating | Key Insight |
|---|---|---|
| Financial Health | ⭐⭐⭐⭐⭐ | 22% FCF CAGR, debt-free, $6.5B cash, expanding margins |
| Moat Strength | ⭐⭐⭐⭐½ | Wide moat; Salesforce is real but non-existential |
| Valuation | ⭐⭐⭐⭐ | 10-26% below fair value; EV/adj FCF 21x vs 30%+ growth |
| Sentiment | ⭐⭐⭐ | Weak stock, strong analyst/institutional base; competitive noise elevated |
| Management | ⭐⭐⭐⭐½ | Founder-led, disciplined capital allocation, first buyback a positive signal |
Investment Thesis
The core thesis is a business-vs-price disconnect. Veeva has grown FCF from ~$450M in FY2021 to $1,415M in FY2026 — a 3x increase in cash generation over five years. The stock is essentially flat to negative over the same period (around $150–165 in mid-2022 vs $158 today). The market has become more pessimistic precisely as the business has grown dramatically more profitable.
The pessimism has three sources: (1) broad SaaS de-rating due to AI disruption fears, (2) Salesforce competitive threat, (3) the Vault CRM migration overhang creating near-term uncertainty. All three are legitimate concerns — none of them is business-ending.
What makes VEEV different from other SaaS-pocalypse victims: Life sciences compliance requirements create a structural floor under Veeva's moat. AI agents will not replace FDA-validated regulatory submission software. Pharma companies will not "vibe-check" their IND applications using a general-purpose AI tool. The domain specificity of Veeva's products is the reason its competitive position is stronger than a generic SaaS player.
The initiation of a $1B buyback at current prices is management making the same bet — that the stock is undervalued relative to the business's intrinsic worth.
Fair Value Range
| Scenario | Fair Value | Upside/Downside |
|---|---|---|
| Bear (Salesforce wins majority, growth slows to 8%) | $110–$135 | -15% to -30% |
| Base (Vault CRM migration succeeds, 12-15% growth) | $185–$215 | +17% to +36% |
| Bull (AI tailwind + margin expansion + buyback acceleration) | $260–$310 | +64% to +96% |
Base case fair value: $195–$215. Current price of $158 represents a 17–35% discount.
Risk Factors
| Risk | Severity | Probability | Mitigation |
|---|---|---|---|
| Salesforce wins >50% of top-20 pharma | High | 20% | Monitor quarterly top-20 commitment count |
| Vault CRM migration delays or customer churn | High | 15% | Track 125+ live customers metric and customer retention |
| General SaaS re-rating continues | Medium | 40% | Multiple compression risk; mitigated by strong absolute business quality |
| Key-man: Peter Gassner departure | Medium | 10% | Founder concentration risk; management bench strong but unproven independently |
| Fidelity/JPMorgan institutional outflows | Low-Medium | 50% | Positioning-driven, not fundamental; BlackRock is adding |
Conviction: 4 / 5 — BUY
Not a 5/5 because: (1) the Salesforce competitive threat is real and the migration window outcome is not yet determined; (2) SBC-adjusted FCF dilutes the raw FCF story; (3) the broader SaaS discount could persist for 12–24+ months before normalizing.
Strong BUY at current levels because the business fundamentals significantly outweigh the market's pessimism. The combination of 22% FCF CAGR, fortress balance sheet, expanding margins, wide regulatory moat, and a 10-26% discount to intrinsic value is a compelling entry.
PORTFOLIO STRATEGIST CONTEXT
Current portfolio holdings: No VEEV position. Life sciences vertical is entirely uncovered.
Portfolio fit: - VEEV adds a pure healthcare-software position with zero overlap against current holdings (which are predominantly enterprise tech, fintech, and financial services SaaS) - Sector diversification: Healthcare/Life Sciences is meaningful given the portfolio's heavy weighting toward enterprise software - Growth profile: Pure growth (no dividend), consistent with growth portion of the "balanced growth + income" transition - Position sizing suggestion: Given conviction (4/5), a 1.5–3% portfolio position is appropriate. The stock's recent volatility (down 50% from highs) warrants a staged entry
Suggested entry strategy: The 52-week low is $148.05 (April 10, 2026). Current price $158 is 7% above the low. Given the Vault CRM migration window creates ongoing uncertainty, a staged entry (e.g., 50% now, 50% on further weakness toward $140–$145) is prudent without sacrificing the core thesis.
ACTION ITEMS
- Add VEEV to Watchlist.md — High conviction, Healthcare sector, "Buy on Downturn" shortlist candidate
- Monitor: Q1 FY2027 earnings (expected June 2026) — track top-20 pharma commitment progress (target: 14+), Vault CRM live customer count, and FY2027 revenue trajectory vs $3.585B guidance
- Catalyst: $1B buyback execution — watch for buyback activity confirmations in next 2 quarters
- Watch: Fidelity and JPMorgan institutional positioning in next 13F filing (Q1 2026 positions due May 2026)
Analysis completed: 2026-04-28 Sources: Yahoo Finance MCP (financial statements, historical prices, analyst recommendations, institutional holders), Web Search (Seeking Alpha, TIKR, Motley Fool Q4 earnings call transcript, Veeva IR, Investing.com, IntuitionLabs, Gurufocus, Markets Daily, Simply Wall St)